BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: The presence of the BIM deletion polymorphism can confer TKI resistance in CML by maintaining a higher ratio of anti-apoptotic exon 3- to pro-apoptotic exon 4-containing BIM transcripts [5].